You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Patent: 7,087,224

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,087,224

Title:	Method of treating anemia by administering IL-1ra
Abstract:	The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.
Inventor(s):	Kay; Jonathan (Newton Centre, ME), McCabe; Dorothy (Moorpark, CA), Newmark; Richard (Newbury Park, CA), Coccia; Marco A. (Camarillo, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	09/969,739
Patent Claims:	see list of patent claims

Details for Patent 7,087,224

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Biovitrum Ab	KINERET	anakinra	VIAL; SUBCUTANEOUS	103950	003	2001-11-14	Start Trial	Amgen Inc. (Thousand Oaks, CA)	2020-10-31	RX		search
Biovitrum Ab	KINERET	anakinra	VIAL; SUBCUTANEOUS	103950	002	2001-11-14	Start Trial	Amgen Inc. (Thousand Oaks, CA)	2020-10-31	RX		search
Biovitrum Ab	KINERET	anakinra	VIAL; SUBCUTANEOUS	103950	001	2001-11-14	Start Trial	Amgen Inc. (Thousand Oaks, CA)	2020-10-31	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 7,087,224

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	0236152	Start Trial
United States of America	2002077294	Start Trial
United States of America	2005106148	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.